ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0859

Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

Kylie Carlson1, Mahmut Kaymakci2, Sebastian E. Sattui3 and Michael Putman4, 1Medical College of Wisconsin, Milwaukee, WI, 2Mayo Clinic, Rochester, MN, 3University of Pittsburgh, Pittsburgh, PA, 4The Medical College of Wisconsin, Milwaukee, WI

Meeting: ACR Convergence 2024

Keywords: Clinical practice guidelines, Cohort Study, giant cell arteritis, Polymyalgia Rheumatica (PMR), risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with PMR. Whether or not this results in an elevated risk of aortic complications is unclear. Our objective was to describe the risk of aortic complications among patients with PMR as compared to those with GCA and a general population control group.

Methods: Using the US-based TriNetX electronic health records database (2000-2024), patients with ≥2 ICD-9/ICD-10-CM diagnostic codes for PMR or GCA between ≥30 days and < 365 days were included. The index date was the first prescription of corticosteroid and was required to occur within 30 days of the first PMR/GCA code. The PMR cohort was also matched to general population controls in 1:3 ratio. Patients were matched by sex, race/ethnicity, regional location, birth year, year of cohort entry, and year of cohort exit. The primary outcome was a composite of aortic aneurysm and aortic dissection or rupture. Unadjusted incidence rates were reported and adjusted hazard ratios (aHR) were calculated using Cox proportional cause-specific hazard models with PMR as the referent category. A sensitivity analysis of patients who had PMR but later developed GCA (PMR-GCA), which set the onset of GCA as the index date, was also performed.

Results: A total of 57,329 were identified, including 17,324 patients with PMR, 4,733 patients with GCA, and 35,272 matched controls from the general population (Table 1). The incidence rate of any aortic complication per 1,000 person years was highest for GCA (11.69) followed by PMR (6.78) and the general population (5.09). Compared to patients with PMR, patients with GCA had a higher risk of any aortic complication (aHR 1.87, 95% confidence interval (CI) 1.54-2.17); the risk was similar for patients from the general population (aHR 0.95, 95% CI 0.84-1.06) (Figure 1). A sensitivity analysis of patients with PMR who developed GCA was also performed; as compared to patients with PMR-GCA, patients with GCA had a similar risk of any aortic complication (aHR 0.85, 95% CI 0.60-1.19); the risk was lower for patients from the general population (aHR 0.41, 95% CI 0.29-0.56) (Figure 2).

Conclusion: Patients with PMR had a lower risk of aortic complications as compared to patients with GCA and a similar risk as compared to those in the general population. Patients with PMR who were later diagnosed with GCA had a similar risk of developing aortic complications from that time point as compared to those who were initially diagnosed with GCA. Our results support the role of large vessel vasculitis screening in patients with GCA but not PMR.

Supporting image 1

Abbreviations: polymyalgia rheumatica (PMR), giant cell arteritis (GCA), standard deviation (SD), no answer/not applicable (NA)

Supporting image 2

Figure 1: Incidence, incident rate ratios, and adjusted hazards for outcomes of interest. Data derived from multiple Cox proportional cause-specific hazards regressions that set PMR as the referent category and adjusted for the following variables, which were assessed at baseline: age, sex, race/ethnicity, methylprednisolone exposure within 30 days of index date, atherosclerosis, diabetes with complications, obesity, smoking, total admissions year prior to index date, and total encounters year prior to index date. Abbreviations: polymyalgia rheumatica (PMR), giant cell arteritis (GCA), 1000 person-years (1000py), HR (hazard ratio)

Supporting image 3

Figure 2: Sensitivity analysis of patients who had PMR at baseline but developed GCA, where the first date of a GCA code was used as a new index date. Data derived from multiple Cox proportional cause-specific hazards regressions that set the PMR-GCA group as the referent category and adjusted for the following variables, which were assessed at baseline: age, sex, race/ethnicity, methylprednisolone exposure within 30 days of index date, atherosclerosis, diabetes with complications, obesity, smoking, total admissions year prior to index date, and total encounters year prior to index date. Abbreviations: polymyalgia rheumatica (PMR), giant cell arteritis (GCA), 1000py (1000 person-years), HR (hazard ratio)


Disclosures: K. Carlson: None; M. Kaymakci: None; S. Sattui: Amgen, 1, AstraZeneca, 5, Bristol-Myers Squibb Foundation, 5, Fresenius Kabi, 6, GlaxoSmithKline, 5, Sanofi, 1, 2; M. Putman: AbbVie/Abbott, 5, Amgen, 5, AstraZeneca, 2, 5, GlaxoSmithKlein(GSK), 2, Novartis, 1, 5.

To cite this abstract in AMA style:

Carlson K, Kaymakci M, Sattui S, Putman M. Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/incidence-of-aortic-aneurysm-dissection-or-rupture-among-patients-with-polymyalgia-rheumatica-and-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-aortic-aneurysm-dissection-or-rupture-among-patients-with-polymyalgia-rheumatica-and-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology